Ipilimumab (CTLA-4 inhibitor) was associated with the highest incidence rate ratio of uveitis (IRR = 30.5) among ICIs, exceeding even ipilimumab plus nivolumab combination therapy (IRR = 20.7) [73]. The gene discussed is CTLA4; the disease is uveitis.